Found: 16
Select item for more details and to access through your institution.
Platelet rich plasma tears for dry eye.
- Published in:
- Ocular Surgery News, 2019, v. 37, n. 18, p. 4
- By:
- Publication type:
- Article
Ophthalmology-based treatments may have effect on seasonal affective disorder.
- Published in:
- Ocular Surgery News, 2017, v. 35, n. 6, p. 5
- By:
- Publication type:
- Article
Dry eye: Emphasis on treatment, not testing.
- Published in:
- Ocular Surgery News, 2017, v. 35, n. 4, p. 6
- By:
- Publication type:
- Article
Office-based cataract surgery: Pros and cons of a controversial idea.
- Published in:
- Ocular Surgery News, 2016, v. 34, n. 14, p. 5
- By:
- Publication type:
- Article
Recombinant human nerve growth factor (cenegermin) for moderate-to-severe dry eye: phase II, randomized, vehicle-controlled, dose-ranging trial.
- Published in:
- BMC Ophthalmology, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12886-024-03564-w
- By:
- Publication type:
- Article
Management of repository corticotropin injection therapy for non‐infectious uveitis: a Delphi study.
- Published in:
- Acta Ophthalmologica (1755375X), 2021, v. 99, n. 6, p. 669, doi. 10.1111/aos.14702
- By:
- Publication type:
- Article
Surgeons take another look at newer glaucoma treatments.
- Published in:
- Ocular Surgery News, 2016, v. 34, n. 10, p. 6
- By:
- Publication type:
- Article
Tolerability of Current Treatments for Dry Eye Disease: A Review of Approved and Investigational Therapies.
- Published in:
- Clinical Ophthalmology, 2024, v. 18, p. 2283, doi. 10.2147/OPTH.S465143
- By:
- Publication type:
- Article
Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial.
- Published in:
- Clinical Ophthalmology, 2022, v. 16, p. 4145, doi. 10.2147/OPTH.S392315
- By:
- Publication type:
- Article
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease.
- Published in:
- Clinical Ophthalmology, 2018, v. 12, p. 1921, doi. 10.2147/OPTH.S175065
- By:
- Publication type:
- Article
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease.
- Published in:
- Clinical Ophthalmology, 2018, v. 12, p. 1921, doi. 10.2147/OPTH.S175065
- By:
- Publication type:
- Article
Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial.
- Published in:
- Clinical Ophthalmology, 2018, v. 12, p. 263, doi. 10.2147/OPTH.S152841
- By:
- Publication type:
- Article
Intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction: A randomized controlled study.
- Published in:
- PLoS ONE, 2022, v. 17, n. 6, p. 1, doi. 10.1371/journal.pone.0270268
- By:
- Publication type:
- Article
Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials.
- Published in:
- Ophthalmology & Therapy, 2022, v. 11, n. 4, p. 1333, doi. 10.1007/s40123-022-00516-9
- By:
- Publication type:
- Article
Results from a Prospective, Open-Label, Phase 4 Pilot Study of Repository Corticotropin Injection for Moderate and Severe Dry Eye Disease.
- Published in:
- Ophthalmology & Therapy, 2022, v. 11, n. 3, p. 1231, doi. 10.1007/s40123-022-00501-2
- By:
- Publication type:
- Article
Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification.
- Published in:
- Ophthalmology & Therapy, 2019, v. 8, n. 2, p. 261, doi. 10.1007/s40123-019-0174-x
- By:
- Publication type:
- Article